N/A N=10 MRI Guided Transrectal Prostate Laser Ablation for Benign Prostatic Hypertrophy (BPH)
BPH · Prostate Hyperplasia · Urinary Frequency/Urgency
Primary: International Prostate Symptom Score (IPSS) Change — -17.5 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=30 Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer
Prostate Cancer
Primary: Safety - Evaluate the Frequency of Treatment Related Adverse Events — 30 Participants
N/A N=25 MRI- Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer
MRI Guided Transurethral Ultrasound Ablation · Localized Prostate Cancer · Ablation Therapy
Primary: Absence of Clinically Significant Cancer (CSC) on Control Biopsy at 1-year Follow-up. — 8 Participants
N/A N=1 Prostate Resection After Microwave Ablation (PRAMA)
Prostate Carcinoma
Primary: The Area of the Transperineal Targeted Microwave Ablation (TMA) Induced Tissue Death Assessed by Triphenyltetrazolium Chloride (TTC) Staining
Phase 2 N=15 MR Image Guided Therapy in Prostate Cancer
Prostate Cancer · Prostatic Neoplasms
Primary: Number of Participants With One Grade 1 Adverse Event, More Than One Grade 1 Adverse Event, and One Grade 2 Adverse Event — 4; 2; 4 Participants
N/A N=27 MR-Guided Laser Interstitial Thermal Therapy in Treating Patients With Prostate Cancer
Stage I Prostate Cancer · Stage II Prostate Carcinoma
Primary: Number of Participants With Undetectable Cancer on MRI-guided Biopsy of Ablation Zone Following Treatment — 26 Participants
N/A N=33 Therapeutic Magnetic Resonance Imaging (MRI)-Guided High Intensity Focused Ultrasound (HIFU) Ablation of Uterine Fibroids
Uterine Fibroids
Primary: Adverse Events/Subject Resulting From HIFU Treatment of the Uterine Fibroids — 2.6 Adverse Event/subject
N/A N=9 Urology of Virginia Case Series
Prostate Cancer · Cancer of the PROSTATE · Prostatic Neoplasm
Primary: Keyword Description of Each Biopsy Sample — 89 percentage significant cancers detected
N/A N=120 Urology San Antonio MRI/MicroUS Comparison
Prostate Cancer
Primary: Number of Participants With Clinically Significant Cancer — 38; 31 Participants
N/A N=9 Magnetic Resonance (MR) Guided Focused Ultrasound Surgery of Uterine Fibroids
Leiomyoma
Primary: Number and Type of Adverse Events — 15 Adverse Events
Phase 3 N=50 MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication
Uterine Leiomyoma · Uterine Fibroids
Primary: Number of Adverse Events — 77; 75 Adverse Events
N/A N=101 Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Lesions
Localized Intermediate Risk Prostate Lesions
Primary: Number of Device and Procedure Related Adverse Events — 24 Number of Adverse Events
N/A N=101 Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Benign Prostatic Hyperplasia (BPH)
Primary: Incidence of Clavien-Dindo Adverse Events (Percentage of Participants) Through 3 Months Post Treatment — 45.5 percentage
N/A N=25 MRI-Guided Lattice Extreme Ablative Dose Radiotherapy For Prostate Cancer
Prostate Cancer · Prostate Adenocarcinoma
Primary: Number of Study Participants Experiencing Treatment-Related Toxicity — 0; 0; 1; 9 Participants
N/A N=6 Focal Prostate Radio-Frequency Ablation
Prostate Cancer
Primary: Negative Biopsy Rate at 6 Months After Focal Bipolar Radio-Frequency Ablation (RFA) — 3; 2; 1 Participants
N/A N=181 Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)
Benign Prostatic Hyperplasia (BPH)
Primary: Proportion of Subjects With Adverse Events (Clavien-Dindo Grading System Grade 2 or Higher or Any Grade 1 Event Resulting in Persistent Disability) — 26; 42 percentage…
N/A N=14 Advanced Image Guidance Utilized in Liver Surgery
Carcinoma, Hepatocellular
Primary: Successful Insertion of Ablation Antenna Into Target Lesion — 100 percentage of participants
N/A N=22 PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer
Metastatic Prostate Cancer
Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants
N/A N=73 Clinical Study of the Mirabilis High-Intensity Focused Ultrasound System for Non-Invasive Treatment of Uterine Fibroids
Uterine Fibroids (Leiomyomas)
Primary: Evaluation of All Adverse Events Encountered — 0; 0.95 Adverse Device Effects / patient
N/A N=147 Sonography Guided Transcervical Ablation of Uterine Fibroids
Menorrhagia
Primary: Percentage of Subjects With ≥ 50% Reduction in Menstrual Blood Loss as Assessed by Pictorial Blood Loss Assessment Chart (PBAC) — 64.8 percentage of participants
Phase 2 N=11 Pilot Study of MRI-Guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids
Uterine Fibroids · Uterine Leiomyomata
Primary: Treatment-related Adverse Events (AE) Per Subject Resulting From HIFU Treatment of the Uterine Fibroids — 1.3 treatment-related AE/patient
N/A N=208 MRI Based Active Selection for Treatment Trial
Prostate Cancer
Primary: Rate of Disease Progression Within the First Two Surveillance Biopsies — 36.1 percentage of participants
N/A N=802 Optimization of Prostate Biopsy - Micro-Ultrasound Versus MRI
Prostate Cancer
Primary: Difference in Detection of Gleason Grade Group 2 or Higher Cancers Using Microultrasonography Plus Systematic Biopsy vs mpMRI/Conventional Ultrasonography Plus…
Phase 2 N=62 High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
Prostatic Neoplasms · Genital Neoplasms, Male · Urogenital Neoplasms
Primary: Primary Endpoint (HIFU): Identification of New Cancers — 85; 49 biopsy-proven cancerous zones
N/A N=108 ExAblate UF V2 System for the Treatment of Symptomatic Uterine Fibroids
Uterine Fibroids
Primary: Percentage of Participants With Leg Pain or Lower Extremity Neuropathy Persisting or Occuring Greater Than 10 Days Following Treatment — 0 Percentage of participants
N/A N=9 Fusion Targeted Biopsy of the Prostate
Prostate Cancer
Primary: Cancer Detection by Targeted and Standard Biopsy Approaches
Phase 2 N=93 Image-Guided Gynecologic Brachytherapy
Cervical Cancer · Uterine Cancer · Vaginal Cancer
Primary: Mean Doses Given — 93.9; 63.2; 58.63 Gy
N/A N=30 MRI-guided Stereotactic Body Radiotherapy (SBRT) With Simultaneous Integrated Boost for Prostate Cancer
Prostate Cancer
Primary: Feasibility of Delivering Stereotactic Body Radiotherapy(SBRT) With Simultaneous Integrated Boost(SIB). — 9; 14; 2; 5 Participants
N/A N=137 Laparoscopic Radiofrequency Ablation (RFA) of Symptomatic Uterine Fibroids
Uterine Fibroids · Uterine Myomas
Primary: Assessment of Menstrual Blood Flow (MBF) at 12 Months Post Procedure — 40.2; 48.8; 59.1; 67.7 Percentage of participants
Phase 2 N=21 High Resolution PET-MRI Before Prostate Cancer HIFU
Prostate Cancer
Primary: Number of Biopsy-proven Cancers (Gleason 6+) That Standard Imaging (mpMRI) Would Have Missed Compared With High Resolution Diffusion-weighted Imaging (DWI) PET-hrMRI on…